VOL. XCIV, NO. 247
★ WIDE MOAT STOCKS COMPARISON ★
NO ADVICE
Friday, January 9, 2026
Stock Comparison
AstraZeneca PLC vs Brookfield Asset Management Ltd.
Compare moat strength, market structure, and segment coverage to understand how each company defends its edge.
AstraZeneca PLC
AZN · London Stock Exchange
Weighted average of segment moat scores, combining moat strength, durability, confidence, market structure, pricing power, and market share.
Full stock profile
Dive deeper into AstraZeneca PLC's moat claims, evidence, and risks.
View AZN analysisBrookfield Asset Management Ltd.
BAM · New York Stock Exchange
Weighted average of segment moat scores, combining moat strength, durability, confidence, market structure, pricing power, and market share.
Full stock profile
Dive deeper into Brookfield Asset Management Ltd.'s moat claims, evidence, and risks.
View BAM analysisComparison highlights
- Moat score gap: Brookfield Asset Management Ltd. leads (75 / 100 vs 71 / 100 for AstraZeneca PLC).
- Segment focus: AstraZeneca PLC has 6 segments (41% in Oncology); Brookfield Asset Management Ltd. has 5 segments (30.3% in Credit).
- Primary market structure: Oligopoly vs Oligopoly. Pricing power: Strong vs Moderate.
- Moat breadth: AstraZeneca PLC has 4 moat types across 3 domains; Brookfield Asset Management Ltd. has 4 across 2.
Primary market context
AstraZeneca PLC
Oncology
Innovator oncology therapeutics (branded prescription medicines)
Global
Hospitals, oncology clinics, payers
Innovator biopharmaceutical company
41%
Brookfield Asset Management Ltd.
Credit
Private credit, opportunistic credit, and multi-strategy credit asset management
Global
Institutional investors, insurance accounts, and private wealth investors
Alternative credit manager / asset manager
30.3%
Side-by-side metrics
Moat coverage
Shared moat types
AstraZeneca PLC strengths
Brookfield Asset Management Ltd. strengths
Segment mix
AstraZeneca PLC segments
Full profile >Oncology
Oligopoly
Cardiovascular, Renal and Metabolism (CVRM)
Competitive
Respiratory & Immunology (R&I)
Oligopoly
Vaccines & Immune Therapies (V&I)
Oligopoly
Rare Disease
Oligopoly
Other Medicines
Competitive
Brookfield Asset Management Ltd. segments
Full profile >Renewable Power and Transition
Oligopoly
Infrastructure
Oligopoly
Real Estate
Oligopoly
Private Equity
Oligopoly
Credit
Oligopoly
Want the full wide moat stocks list?
Browse the full ranking of wide moat stocks, updated with moat scores and segment context.
View the moat stocks listLooking for expansion-stage stocks?
Proven models entering the expansion stage with unit economics that work.
View expansion-stage stocksCuration & Accuracy
This directory blends AI‑assisted discovery with human curation. Entries are reviewed, edited, and organized with the goal of expanding coverage and sharpening quality over time. Your feedback helps steer improvements (because no single human can capture everything all at once).
Details change. Pricing, features, and availability may be incomplete or out of date. Treat listings as a starting point and verify on the provider’s site before making decisions. If you spot an error or a gap, send a quick note and I’ll adjust.